Resource id #3DrugId:1d00000039resource(4) of type (mysql result) Drug Search

Main    A    B    C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z    Main   

Drug ID: 1d00000039

Drug Name: Albuterol and Ipratropium

Generic Names: Combivent

Category: Bronchodilator

Legal Status: Non Opioid Prescription only drug


Indication for Mother: Category C
Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Recommended Dose: The recommended dose is one 3 mL vial administered 4 times per day.

Recommended In: This combination medication contains beta-adrenergic (sympathomimetic) and anticholinergic bronchodilator, prescribed for chronic obstructive pulmonary disease (COPD). It relaxes airway muscles that result in easy breathing.

Directions For Use: It comes as a solution (liquid) to inhale by mouth using a nebulizer, as directed by your physician.

Storage: Store between (2C and 25C). Protect from light.

Dosage Forms: Liquid Inhalation

Side Effects: Body As A Whole - Pain, chest pain.

Gastrointestinal - Diarrhea, indigestion, nausea.

Musculoskeletal - Leg cramps.

Respiratory- Lung inflammation, lung disease, inflammation of pharynx, pneumonia.

Genitourinary - Urinary tract infection.

Eye- Mydriasis(dilation of the pupil).

In Case of Overdose: The effects of overdosage are expected to be related primarily to albuterol sulfate. Acute overdosage with ipratropium bromide by inhalation is unlikely since ipratropium bromide is not well absorbed systemically after aerosol or oral administration. Manifestations of overdosage with albuterol may include anginal pain, hypertension, hypokalemia, tachycardia with rates up to 200 beats per minute, metabolic acidosis, and exaggeration of the pharmacologic of some drugs. As with all sympathomimetic aerosol medications, cardiac arrest and even death may be associated with abuse. Dialysis is not appropriate treatment for overdosage of albuterol as an inhalation aerosol; the judicious use of a cardiovascular beta-receptor blocker, such as metoprolol tartrate may be indicated.

Avoid If: Caution should be exercised in patients with history of increased eye pressure, difficulty in urinating, enlarged prostate, seizures, overactive thyroid, high blood pressure, irregular heartbeat, diabetes, heart, liver or kidney disease, who are taking other medications, any allergy, during pregnancy and breastfeeding.

It may cause dizziness, blurred vision, or drowsiness, do not drive a car or operate machinery while taking this medication.

It may cause severe breathing problems, if it is so consult with your healthcare provider.

Avoid contact with eyes.

Drug Interaction: Anticholinergic agents

There is potential for an additive interaction with concomitantly used anticholinergic medications. Therefore, avoid co-administration of Albuterol and Ipratropium Inhalation Aerosol with other anticholinergic-containing drugs.

Beta-adrenergic agents

Caution is advised in the co-administration of Albuterol and Ipratropium Inhalation Aerosol and other sympathomimetic agents due to the increased risk of adverse cardiovascular effects.

Beta-receptor blocking agents and albuterol inhibit the effect of each other. Beta-receptor blocking agents should be used with caution in patients with hyperreactive airways.


The ECG changes and/or hypokalemia which may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.

Monoamine oxidase inhibitors or tricyclic antidepressants

Albuterol and Ipratropium Inhalation Aerosol should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants or within two weeks of discontinuation of such agents because the action of albuterol on the cardiovascular system may be potentiated. Consider alternative therapy in patients taking MAOs or tricyclic antidepressants.

Main    A    B    C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z    Main